{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:56:37Z","timestamp":1785858997134,"version":"3.56.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1097\/bor.0b013e3282f4eff5","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T13:15:15Z","timestamp":1236258915000},"page":"198-202","source":"Crossref","is-referenced-by-count":65,"title":["Refractory gout: what is it and what to do about it?"],"prefix":"10.1097","volume":"20","author":[{"given":"Edward","family":"Fels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Sundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210128","first-page":"2303","article-title":"Clinical gout and pathogenesis of hyperuricemia","author":"Becker","year":"2005"},{"key":"R2-14-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.57.9.545","article-title":"Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout","volume":"57","author":"Perez-Ruiz","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"R3-14-20210128","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R4-14-20210128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R5-14-20210128","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11926-007-0041-y","article-title":"Uricase and other novel agents for the management of patients with treatment-failure gout","volume":"9","author":"Sundy","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"R7-14-20210128","first-page":"272","article-title":"Multicenter longitudinal study of disease characteristics in patients with treatment failure gout [abstract]","volume":"65","author":"Sundy","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R8-14-20210128","first-page":"271","article-title":"Quality of life in patients with treatment failure gout [abstract]","volume":"65","author":"Sundy","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R9-14-20210128","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-14-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s100670050005","article-title":"How is gout managed in primary care? A review of current practice and proposed guidelines","volume":"19","author":"Pal","year":"2000","journal-title":"Clin Rheumatol"},{"key":"R11-14-20210128","first-page":"44","article-title":"Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout","volume":"30","author":"de Klerk","year":"2003","journal-title":"J Rheumatol"},{"key":"R12-14-20210128","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"R13-14-20210128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R14-14-20210128","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/00007611-197911000-00004","article-title":"Severe hypersensitivity reactions to allopurinol","volume":"72","author":"Lang","year":"1979","journal-title":"South Med J"},{"key":"R15-14-20210128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.1780290111","article-title":"The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality","volume":"29","author":"Singer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"R16-14-20210128","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R17-14-20210128","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R18-14-20210128","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R19-14-20210128","first-page":"S679","article-title":"A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and refractory gout [abstract]","volume":"52","author":"Sundy","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R20-14-20210128","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R21-14-20210128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","article-title":"Rasburicase treatment in severe tophaceous gout: a novel therapeutic option","volume":"25","author":"Moolenburgh","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R23-14-20210128","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"R24-14-20210128","first-page":"2171","article-title":"Urate-oxydase for gouty arthritis in cardiac transplant recipients","volume":"20","author":"Rozenberg","year":"1993","journal-title":"J Rheumatol"},{"key":"R25-14-20210128","first-page":"392","article-title":"Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients: a report of three cases","volume":"62","author":"Rozenberg","year":"1995","journal-title":"Rev Rheum Engl Ed"},{"key":"R26-14-20210128","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/ndt\/gfh629","article-title":"Urate oxidase (rasburicase) for treatment of severe tophaceous gout","volume":"20","author":"Vogt","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R27-14-20210128","first-page":"1955","article-title":"Learning how and when to employ uricase as bridge therapy in refractory gout","volume":"34","author":"Terkeltaub","year":"2007","journal-title":"J Rheumatol"},{"key":"R28-14-20210128","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","article-title":"The role of interleukin-1 and the inflammasome in gout: implications for therapy","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R29-14-20210128","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1172\/JCI29404","article-title":"Gout: new insights into an old disease","volume":"116","author":"Martinon","year":"2006","journal-title":"J Clin Invest"},{"key":"R30-14-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R31-14-20210128","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/art.21238","article-title":"Innate immunity conferred by toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation","volume":"52","author":"Liu-Bryan","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R32-14-20210128","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.4049\/jimmunol.177.9.6370","article-title":"Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals","volume":"177","author":"Scott","year":"2006","journal-title":"J Immunol"},{"key":"R33-14-20210128","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.138.10.3213","article-title":"Interleukin 1 (IL 1) as a mediator of crystal arthritis: stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1","volume":"138","author":"Di Giovine","year":"1987","journal-title":"J Immunol"},{"key":"R34-14-20210128","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/anr.1780321114","article-title":"Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes","volume":"32","author":"Guerne","year":"1989","journal-title":"Arthritis Rheum"},{"key":"R35-14-20210128","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/art.1780340716","article-title":"Monocyte-derived neutrophil chemotactic factor\/interleukin-8 is a potential mediator of crystal-induced inflammation","volume":"34","author":"Terkeltaub","year":"1991","journal-title":"Arthritis Rheum"},{"key":"R36-14-20210128","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"R38-14-20210128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00296-005-0617-7","article-title":"Successful treatment of chronic tophaceous gout with infliximab (Remicade)","volume":"26","author":"Fiehn","year":"2006","journal-title":"Rheumatol Int"},{"key":"R39-14-20210128","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/ard.2003.015743","article-title":"Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with antitumour necrosis factor alpha as a new therapeutic option","volume":"63","author":"Tausche","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R40-14-20210128","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0022-3565(24)36490-0","article-title":"Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles","volume":"280","author":"Roch-Ramel","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R41-14-20210128","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using antihyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R42-14-20210128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0026-0495(88)90098-4","article-title":"Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial","volume":"37","author":"Bastow","year":"1988","journal-title":"Metabolism"},{"key":"R43-14-20210128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","article-title":"Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout","volume":"42","author":"Feher","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R44-14-20210128","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/ard.60.10.984a","article-title":"Fenofibrate: a new treatment for hyperuricaemia and gout?","volume":"60","author":"Hepburn","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R45-14-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10067-002-0658-1","article-title":"Long-term remission from gout associated with fenofibrate therapy","volume":"22","author":"Hepburn","year":"2003","journal-title":"Clin Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e3282f4eff5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:27:25Z","timestamp":1738978045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200803000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3282f4eff5","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}